Metabolic Syndrome Is a Strong Risk Factor for Minor Ischemic Stroke and Subsequent Vascular Events

Guang-Sheng Wang¹, Dao-Ming Tong¹*, Xiao-Dong Chen¹, Tong-Hui Yang¹, Ye-Ting Zhou², Xiao-Bo Ma³

¹ Department of Neurology, Affiliated Shu Yang People’s Hospital, XuZhou Medical University, XuZhou, China, ² Department of Clinical Research, Affiliated Shu Yang People’s Hospital, XuZhou Medical University, XuZhou, China, ³ Department of science and education, Affiliated Shu Yang People’s Hospital, XuZhou Medical University, XuZhou, China

* tongdaoming@163.com

Abstract

Background

Minor ischemic stroke (MIS) represents a major global public health problem worldwide due to high incidence. The aim of this study was to investigate whether metabolic syndrome (MetS) is a strong risk for MIS and subsequent vascular events (SVE).

Methods

A retrospective cohort study was performed examining symptomatic MIS in a Chinese neurologic outpatient population aged over 25 years without history of stroke. MetS was defined using the International Diabetes Federation criteria. MIS was diagnosed by magnetic resonance imaging-diffusion weighted images or fluid-attenuated inversion recovery.

Results

Of 1361 outpatients, a total of 753 (55.3%) patients were diagnosed with MIS; of them, 80% had a score of 0 using the MIS had a 0 score on the National Institutes of Health Stroke Scale. Among these, 303 (40.2%) individuals with MIS were diagnosed with MetS. Diagnosed of MIS with MetS significantly correlated with abdominal obesity (30.7% v.s 18.0%), hypertension (91.1% v.s 81.6%), increased blood glucose (6.9±2.4 v.s 5.0±0.4), dyslipidemia (78.2% v.s 48.2%), and SVE (50.5% v.s 11.3%) when compared with the controls group. On adjusted analysis, the risk of SVE was also significantly associated with three additional MetS criterion (RR, 9.0; 95% CI, 5.677–14.46). Using Cox proportional analysis, risk of SVE in patient with MIS was significantly associated with MetS (RR, 3.3; 95% CI, 1.799–6.210), older age (RR, 1.0; 95% CI, 1.001–1.048), and high blood glucose (RR, 1.1; 95% CI, 1.007–1.187).
Conclusions
The MetS is a strong risk factor for MIS, and patients presenting with MIS and MetS are at a high risk of SVE. Further studies are required to determine the improvement of Mets prevention in the reduction of MIS and SVE.

Introduction
Minor ischemic stroke (MIS) has become an important public health problem, particularly as several epidemiological studies have reported an incidence of up to 55%-74% in metropolitan regions [1], [2]. Recently, studies have demonstrated that many well-known vascular risk factors such as hypertension, smoking, diabetes, cholesterolemia, atrial fibrillation, heart disease, and being overweight or obese remain significantly associated with ischemic stroke in both the general population and those at high risk of stroke [3], [4]. In addition, some new risk factors, including dyslipidemia, increased blood levels of C-reactive protein, carotid intima-media thickness, metabolic syndrome (MetS), older age, and gender have been identified [4], [5]. These risk factors increase the risk of cardiovascular diseases and ischemic strokes [6]–[8]. In particular, abdominal obesity, dyslipidemia, hyperglycemia, and symptomatic hypertension are together regarded as the four important risk factors for ischemic stroke and are referred to as MetS [5], [8–10]. Previous hospital based studies have confirmed that MetS is not only a risk factor for intracranial atherosclerotic stroke [11], [12], but it is also more likely to cause acute severe ischemic stroke [13–15]. Moreover, the important role of inflammation and arterial stiffness has been demonstrated in acute ischemic stroke patients with MetS [16], [17]. However, few studies have assessed the role of MetS as a strong risk factor for MIS, and there is limited data showing that these patients are more likely to present with subsequent vascular events (SVE). Thus, this retrospective cohort study analyzed data from neurologic outpatients without history of stroke. The overall aim was to assess whether MetS was associated with increased risk of MIS and SVE.

Methods
Ethics Statement
The study was approved by the Ethical Committee on Clinical Research of the Shuyang People’s hospital, China. The study was in full compliance with the Helsinki declaration, and solely required de-identification of all personal information related to the already collected clinical data without requirement of informed consent.

Study population
A population-based retrospective cohort study was performed recruiting consecutive new patients for assessment between January 2011 and February 2013. All were registered neurologic outpatients at a tertiary teaching hospital in northern Jiangsu, China. Symptomatic outpatients (n = 1361), clinically only having had their initial visit and having undergone a magnetic resonance imaging (MRI) study of the brain, were enrolled. To be eligible, subjects were required to be >25 years old, and live in one of 38 villages or towns, or one urban center in Shu Yang of northern China. Included patients were also required to have a follow-up assessment at 6 months.
Assessment of minor ischemic stroke

Based on radiographic imaging, ischemic infarct can be divided into either a lacunar stroke or non-lacunar stroke. MIS is usually indicated by the lacunar stroke subtype, due to small vessel disease (SVD), although this is not always the case. However, the trial of ORG 10172 in acute stroke treatment denoted five ischemic stroke subtypes, and these may also contribute to MIS. These include arterothrombotic MIS, cardioembolic MIS, and non-SVD MIS due to another etiology. Therefore, for the purposes of this study, the inclusion criteria of MIS were as follows: (1) first visit indicating minor brain symptoms, with or without minor positive signs of stroke, and measured as ≤3 on the National Institutes of Health Stroke Scale (NIHSS) [18]; (2) an MRI displaying visible MIS as a small infarcts within 24 hours of initial presentation [19], or lacunar lesions [20] or increased brain signal using diffusion weighted imaging (DWI) or fluid-attenuated inversion recovery (FLAIR), with a location in the subcortical white matter, the basal ganglia, or the brain stem. Exclusion criteria were as follows: (1) age <25 years; (2) previous history of stroke diagnosed; or (3) an NIHSS score of >3 on first visit.

Definition of the MetS

Subjects were diagnosed with MetS if they met at least three of the following revised American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement criteria [12]: (1) an elevated waist circumference of >102 cm for men and >88 cm for women; (2) elevated triglycerides >150 mg/dL (1.7 mmol/l); (3) reduced high-density lipoprotein cholesterol of <40 mg/dL (1.03 mmol/l) for men and <50 mg/dL (1.3 mmol/l) for women; (4) elevated blood pressure ≥130 mm Hg systolic blood pressure or ≥80 mm Hg diastolic blood pressure; (5) elevated fasting blood glucose ≥100 mg/dL (5.6 mmol/l).

For Asian populations, the International Diabetes Foundation thresholds for abdominal obesity were used: waist circumferences ≥90 cm in men and ≥80 cm in women [12].

Determination of subsequent vascular event (SVE)

SVE was defined as a transient ischemic attack (TIA), the presence of transient nonfocal cerebrovascular symptoms, deterioration of cerebrovascular symptoms, or recurrent infarction, in addition to a Rankin scale score ≥ 2 during a follow-up visit.

Data Collection

Throughout the study, trained researchers utilized instruments to collect data. Anthropometric parameters and blood pressure were measured by standard methods. Fasting plasma glucose and lipid profiles were measured in a central laboratory. The following vascular risk factors were obtained from registered outpatients. Current smokers were defined as those who had smoked at least one cigarette per day during the 12 months prior to assessment. Excessive alcohol intake was defined as consumption of ≥30 g of alcohol per day. Baseline BMI was categorized as normal (BMI < 25 kg/m2), overweight (25–30 kg/m2), or obese (greater than 30 kg/m2). Waist circumference was measured if the patient had an overweight or obese. Hypertension was defined as having a clinical history of hypertension, or 2 or more previously documented systolic blood pressures greater than 160 mmHg or diastolic blood pressures greater than 90 mmHg. Diabetes mellitus was deemed present if the patient gave a history of diabetes that was confirmed by medical records, or had a blood glucose concentration greater than 11 mmol/l. Dyslipidemia was deemed present if total venous plasma cholesterol levels were greater than 6.0 mmol/l, the low-density lipoprotein fraction was greater than 3.0 mmol/l, triglyceride levels were greater than 1.7 mmol/l, and high density lipoprotein cholesterol less than
1.03 mmol/l in males or less than 1.3 mmol/l in females. Coronary heart disease was defined as a history of an acute myocardial infarction or angina pectoris. Atrial fibrillation, as indicated by an electrocardiogram during the initial visit, or by medical records.

All patients underwent a brain MRI within 24 hours of the first visit. The MRI was performed with 1.5-T equipment (Siemens). All MRIs were reviewed by a neuroradiologist and a neurologist who were blinded to the study. The examiners specifically assessed the presence of hyperintense lesions using FLAIR or DWI. The maximum diameters (in mm), number, and location of lesions were recorded in detail for each patient.

The NIHSS criteria were used to assess the symptom severity of each outpatient at the time of initial visit. All patients with MIS or TIA were given aspirin therapy (100 mg daily). Hypertension was treated with clinically appropriate agents. Patients diagnosed diabetes mellitus were provided with specialist treatment as required. In order to further investigate MIS patients with or without SVE during the 180-day follow-up assessment, information was gathered by a neurological specialist by telephone. For patients who died during follow-up, information was obtained from relatives and/or hospital records.

Statistical analyses

Statistical analyses were carried out using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Discrete data are presented as numbers and percentages, means and standard deviations, medians and interquartile ranges, or proportions with 95% confidence intervals. Accordingly, chi-square tests were summarized as numbers with percentages. Independent t test and Mann-Whitney U test were used to compare differences in continuous variables between the two groups. Chi-squared tests and Pearson's correlation coefficients were used to explore the relationships between baseline variables. Age-and multivariate-adjusted risk ratios (RR) and 95% confidence intervals (CIs) were estimated with the use of the logistic-regression model or Cox proportional hazards model to examine MetS baseline status and determine whether the variables played a role in the risk of incident MIS and its SVE. For all statistical analyses, a two-sided $P<0.05$ was considered statistically significant.

Results

A total of 1361 subjects enrolled in this study. Of these, 608 patients were excluded. 268 patients with a final diagnosis of TIA, 139 patients with primary migraine without infarction, 137 patients with peripheral vertigo, 51 patients with other brain episodes, and 13 patients with infarction and an initial NIHSS score $>3$. Eventually, 753 outpatients with a mean age of 60±11.6 years (range: 25–84 years) were included in the investigation.

Baseline characteristics of the patients with MIS are shown in Table 1. 753 patients with MIS were diagnosed using MRI-FLAIR or DWI within 24 hours of the initial visit (the execution rate of DWI only up to 53%). Of them, 80% of patients with MIS had a score of 0 using NIHSS criteria, while only 20% had scores of 1–3. The overall prevalence of MIS at baseline was 55.3%. The main type of symptom in patients with MIS were non-focal neurologic symptoms (90%) and a large proportion of these patients had multiple small infarcts (91.6%) on MRI (Fig 1). The most common affected vascular territory was in the anterior circulation artery (ACA) regions (55.5%), followed by both the ACA and posterior cerebral artery (PCA) (40.9%). Only 3.6% cases were involved only the PCA. The median size of infarcts was 5.0 mm (range, 0.2–20.0).

Of the MIS patients, 303 (40.2%) were identified to have MetS, while 450 (59.8%) did not. The distribution of individual components MetS criteria in patients with MIS is exhibited in
Table 1. Baseline characteristics of the MIS in neurologic outpatients (n = 753).

| Characteristic                  | Value                  |
|--------------------------------|------------------------|
| Age,(years, mean ±SD)          | 60 ±11.6               |
| Female sex, n(%)               | 374(49.7)              |
| Nonfocal neurologic symptoms, n(%) | 678(90%)           |
| Dizziness/vertigo              | 201(29.6)              |
| Headache/migraine variation    | 165(24.3)              |
| Headache with dizziness        | 181(26.7)              |
| Others                         | 131(19.3)              |
| Focal neurologic symptoms, n(%) | 75(10%)               |
| No. of initial NIHSS score met MIS, n(%) |                     |
| 0 score                        | 602(80.0)              |
| 1 score                        | 119(15.8)              |
| 2 score                        | 28(3.7)                |
| 3 score                        | 0(0.5)                 |
| MRI findings, n(%)             |                        |
| DWI positive lesions           | 172(43.0)              |
| FLAIR positive lesions         | 753(100.0)             |
| Median time of onset to MRI (days, range) | 15(1898.9)        |
| Median number of lesions (range) | 8(1–110)              |
| Median size of infarcts (mm, range) | 5.0(0.3–20.0)        |
| Multiple infarction(%)         | 685(91.6)              |
| Brain atrophy(%)               | 12(1.6)                |
| Leukoaraiosis(%)               | 49(6.6)                |
| Location of MIS                |                        |
| ACA                            | 418(55.5)              |
| PCA                            | 27(3.6)                |
| ACA+PCA                        | 308(40.9)              |

MIS = minor ischemic stroke; DWI = diffusion-weighted imaging; FLAIR = fluid-attenuated inversion recovery; ACA = anterior circulation artery; PCA = posterior circulation artery.

doi:10.1371/journal.pone.0156243.t001

Table 2. In MIS patients with MetS, the most frequent single criterion that was met was a hypertension (91.1%), followed by an increased blood glucose and raised TC.

On those traditional risk factors, MetS was significantly correlated with the abdominal obesity (30.7% v.s 18.0%), hypertension (91.1% v.s 81.6%), diabetes mellitus (18.8% v.s 0.01%), increased blood glucose (6.9±2.4 v.s 5.0±0.4), and dyslipidemia (78.2% v.s 48.2%). The MIS patients with MetS were significantly more likely to present with SVE (50.5% v.s 11.3%) than those without MetS (Table 3).

Outcome data were available among patients with MIS. The risk of death was similarly low in patients with or without MetS (1.0% v.s 0.8%) during the follow-up. Three patients with MetS died from the progression of stroke, and two additionally died from stroke itself. Two patients without MetS died from lung cancer.

Adjusted for age and sex, only three individual MetS components were significantly associated with the risk of developing MIS associated SVE (Table 4). These included hypertension (RR,2.6; 95%CI, 1.020–6.544;p = 0.045), high blood glucose (RR, 2.8; 95% CI, 1.938–4.113; p<0.001), and increased GC (RR, 3.2; 95% CI, 1.753–5.603; p<0.001), in addition to older age (RR, 1.0; 95% CI, 1.022–1.072; p<0.001). The frequency of the SVE in MIS patients increased
over the number of positive individual MetS factors (from 42.9% at a threshold of three MetS criteria to 91.7% at a threshold of five MetS criteria) (Figure A in S1 File).

In correlate analysis, SVE in MIS patients were positively correlated with the frequency of individual MetS factors ($r = 0.466$, $P < 0.001$). Using a logistic model adjusted to include the number of MetS criteria from 0 to 5, the risk ratio for SVE was also significantly associated with three additional MetS criterion (50.5% verse 11.3%; RR, 9.0; 95%CI, 5.677–14.46; $P < 0.001$) (Fig 2).

Cox proportional risk analysis demonstrated that only the MetS (RR, 3.3; 95% CI, 1.799–6.210; $p < 0.0001$), older age (RR, 1.0; 95% CI, 1.001–1.048; $p = 0.039$), and high blood glucose

### Table 2. Distribution of individual components meeting MetS criteria in MIS patients with or without MetS.

| Variable                     | MIS with MetS (N = 303) | MIS without MetS (N = 450) | $P$ |
|------------------------------|-------------------------|---------------------------|-----|
| MetS individual components   |                         |                           |     |
| Abdominal obesity, n (%)     | 93(30.7)                | 81(18.0)                  | <0.001 |
| Hypertension, n (%)           | 276(91.1)               | 367(81.6)                 | <0.001 |
| Raised fasting plasma glucose| 234(77.2)               | 17(3.8)                   | <0.001 |
| Raised TG, n (%)             | 205(67.7)               | 189(42.0)                 | <0.001 |
| Decreased HDL-C              | 37(10.4)                | 26(4.7)                   | 0.002 |
| No. of MetS components met    |                         |                           |     |
| 0                            | 0(0)                    | 33(7.3)                   |     |
| 1                            | 0(0)                    | 203(45.1)                 |     |
| 2                            | 0(0)                    | 214(47.6)                 |     |
| 3                            | 235(77.2)               | 0(0)                      |     |
| 4                            | 56(18.4)                | 0(0)                      |     |
| 5                            | 12(4.0)                 | 0(0)                      |     |

MIS = minor ischemic stroke; MetS = metabolic syndrome; TG = triglycerides; LDL-C = low density lipoprotein cholesterol.

doi:10.1371/journal.pone.0156243.t002
Discussion

This study assessed 1361 neurology outpatients. 753 (55.3%) patients with recent MIS were identified using MRI, and 80% of these patients had a score of 0 using NIHSS criteria. 40.2% of MIS patients fulfilled three or more MetS criteria at their first-ever visit, supporting the conclusion that the MetS factors assessed in this study may be highly prevalence in MIS patients.

Table 3. The results of univariate analysis in patients with MetS and without MetS.

| Variable                        | MIS with MetS (N = 303) | MIS without MetS (N = 450) | P Value |
|---------------------------------|-------------------------|----------------------------|---------|
| Male gender, n (%)              | 165(54.5)               | 214(47.6)                  | 0.063   |
| Age (years, mean ±SD)           | 60.6±10.2               | 59.9±12.0                  | 0.683   |
| BMI (kg/m2, mean ±SD)           | 24.7±3.0                | 23.5±3.2                   | 0.004   |
| Abdominal obesity, n (%)        | 93(30.7)                | 81(18.0)                   | <0.001  |
| Hypertension, n (%)             | 276(91.1)               | 367(81.6)                  | <0.001  |
| Diabetes mellitus, n (%)        | 57(18.8)                | 6(0.01)                    | <0.001  |
| Heart disease, n (%)            | 10(0.3)                 | 7(0.02)                    | 0.114   |
| Atrial fibrillation, n (%)      | 9(0.3)                  | 6(0.01)                    | 0.115   |
| Smoking, n (%)                  | 106(35.0)               | 118(26.2)                  | 0.979   |
| Alcohol drinker, n (%)          | 87(32.0)                | 125(27.8)                  | 0.780   |
| Blood glucose (mmol/l, mean ±SD)| 6.9±2.4                 | 5.0±0.4                    | <0.001  |
| Dyslipidemia, n (%)             | 237(78.2)               | 217(48.2)                  | <0.001  |
| SBP, mm Hg (mean ±SD)           | 153.1±22.1              | 150.5±21.2                 | 0.336   |
| DBP, mm Hg (mean ±SD)           | 97.4±10.9               | 94.8±11.6                  | 0.073   |
| Number of lesions on MRI (mean ±SD) | 11±12.4             | 10±14.3                    | 0.828   |
| Size of lesion on MRI (mm, mean ±SD) | 1.2±1.7               | 1.0±1.6                    | 0.549   |
| Initial NIHSS score (mean ±SD)  | 0.3±0.6                 | 0.2±0.5                    | 0.349   |
| Subsequent vascular event, n (%)| 153(50.5)               | 51(11.3)                   | <0.001  |
| Mortality, n (%)                | 3(1.0)                  | 4(0.9)                     | 0.887   |

MIS = minor ischemic stroke; MetS = metabolic syndrome; BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure.

doi:10.1371/journal.pone.0156243.t003

Table 4. MetS individual components and the risk of SVE in patients with MIS during follow-up (n = 753), adjusted for age and sex.

| Variable                        | MIS with SVE (N = 204) | MIS without SVE (N = 549) | RR (95% CI) | P Value |
|---------------------------------|------------------------|---------------------------|-------------|---------|
| Male gender, n (%)              | 105(51.5)              | 270(49.2)                 | 1.3(0.797–2.189) | 0.280   |
| Age (y, mean ±SD)               | 63.4±11.0              | 59.0±11.2                 | 1.0(1.022–1.072) | 0.000   |
| MetS, n (%)                     | 156(76.5)              | 147(26.8)                 | 1.6(0.818–3.196) | 0.176   |
| Abdominal obesity, n (%)        | 63(30.9)               | 111(20.2)                 | 1.1(0.968–1.147) | 0.255   |
| Hypertension, n (%)             | 189(92.6)              | 453(82.5)                 | 2.6(1.020–6.544) | 0.045   |
| Blood glucose, (mmol/l, mean ±SD)| 7.2±2.9               | 5.2±0.7                   | 2.8(1.938–4.113) | <0.001  |
| TG, n (%)                       | 158(77.3)              | 273(49.7)                 | 3.2(1.753–5.603) | <0.001  |
| HDL-C                           | 31(15.4)               | 21(3.8)                   | 1.0(0.411–2.643) | 0.930   |

MIS = minor ischemic stroke; SVE = subsequent vascular event; MetS = metabolic syndrome; TG = triglycerides; HDL-C = High density lipoprotein cholesterol; RR = risk ratio; CI = confidence interval.

doi:10.1371/journal.pone.0156243.t004

(RR, 1.1; 95% CI, 1.007–1.187; p = 0.033) were significantly related to SVE in patient with MIS (Table 5).
MetS factors were significantly higher in patients with serious ischemic stroke compared to controls [13], [14], and patients with these factors were at higher risk of recurrent stroke than those without MetS [15], [21]. Our study confirmed that neurologic outpatients with recently diagnosed MIS may also be at risk of MetS. Thus, we believe that MetS is a contributing factor in conditions ranging from severe stroke to MIS.

Fig 2. Adjusted risk of SVE among Patients with MIS, According to Number of MetS Criteria Met. Adjusted risk of SVE show that MIS patients with MetS had significantly frequent SVE than those MIS patients without MetS during the 6-months follow-up (Risk ratio = 9; 95% CI, 20.29–39.31; P = 0.000).

doi:10.1371/journal.pone.0156243.g002

Table 5. Cox analysis of the association of outcome for MIS patients with or without SVE.

| Variable                  | MIS with SVE (N = 204) | MIS without SVE (N = 549) | RR (95%CI)     | P Volume |
|---------------------------|------------------------|---------------------------|----------------|----------|
| Age (years, mean ±SD)     | 63.4±11.0              | 59.0±11.2                 | 1.0(1.001–1.048) | 0.039    |
| Blood glucose, (mmol/l, mean ±SD) | 7.2±2.9             | 5.2 ±0.7                  | 1.1(1.007–1.187) | 0.033    |
| MetS, n (%)               | 156(76.5)              | 147(26.8)                 | 3.3(1.799–6.210) | <0.001   |

MIS = Minor ischemic stroke; SVE = subsequent vascular event; MetS = metabolic syndrome; RR = risk ratio; CI = confidence interval.

doi:10.1371/journal.pone.0156243.t005
Previous studies demonstrated that the relationship between MetS factors and ischemic stroke were independent. Nira et al indicated that individuals with MetS without diabetes exhibited a 1.49-fold increased risk of ischemic stroke or TIA [22]. More recently, one study showed that only the hypertensive trait among MetS factors was associated with a significantly elevated risks of ischemic stroke [23]. Our data demonstrated that MIS patients with MetS had higher abdominal obesity, a hypertension, a higher diabetes mellitus ratio or increased blood glucose, higher dyslipidemia ratio, and more frequent SVE than those without MetS. These finding were similarly recognized in previous community studies [3], [4] and in a recent study [24]. However, using a multivariable analysis, the older age, hypertension, increased blood glucose, and higher triglycerides were found to be independent predictors of SVE. A recent study showed that serum hyperglycemia contributed to poor functional outcomes [25]. Furthermore, some studies have shown that older patients with ischemic stroke are more likely to have worse outcome [26], [27]. In our current study, a Cox proportional risk analysis confirmed that MetS, older age, and high blood glucose were significantly related to SVE in patient with MIS. Moreover, MetS was identified to be the biggest risk factor for development of SVE in MIS patients (RR, 3.3). On adjusted analysis, the risk of SVE was also significantly associated with three additional MetS criterion. Our current findings support the use of three criteria as a cutoff point for the identification of at-risk patients. From a practical perspective, prophylactic measures for outpatients diagnosed with MetS with MIS are currently less widely implemented than for hospitalized patients with serious ischemic stroke. Therefore, we believe that these findings are likely to be essential for planning and implementation of prevention and treatment programs.

Limitations of this retrospective cohort study should be mentioned. Firstly, some previous studies showed that a higher proportion of females had MetS compared to males [28], [29]. However, our current study did not result in a difference between sexes. As our study was based on a randomly selected subgroup of Neurologic outpatients, the presence confounding could not entirely be excluded. However, of the included study population, 94% of subjects lived in one of 38 villages or towns, while only 6% were from the county town. This allowed us to determine the proportion of patients with MIS in the community who were admitted to the neurologic outpatient clinic, suggesting at most a very small bias in our study population. Secondly, the frequency of SVE has previously been correlated with the presence of intracranial artery stenosis or carotid plaque [30], [31], suggesting that these factors may contributed to SVE in MetS patients with uncertain diagnoses. Furthermore, the presence of asymptomatic intracranial artery stenosis due to MetS has been confirmed by recent study [32]. Unfortunately, most of the MIS patients with MetS in the present study did not have available vascular imaging and transcranial color-coded Doppler sonography data. In addition, the diagnosis of MetS was based on a single assessment comprising a number of MetS factors. Some vascular risk factors assessed at the 6 months follow-up may have been affected by medication provided over this period. This may have reduced the associations found in this study. However, the individual MetS factors pertaining to bodily measurements or laboratory data were prospectively collected and were less likely to be biased. Therefore, we believe that the high prevalence of MetS in MIS patients was unlikely to be overestimated in our study.

In conclusion, our outpatient-based study revealed that the prevalence of MetS was high in patients with MIS, and that these patients were more likely to be at risk of SVE. Further assessing methods to prevent and improve the features of MetS may be important to reduce MIS and associated SVE.
Supporting Information

S1 File. Figure A. The frequency of SVE in MIS patients increased with the number of positive individual MetS factors (from 42.9% at a threshold of three MetS criteria to 91.7% at a threshold of five MetS criteria). Table A. Minimal data set. Multivariate and Cox analysis of the association of outcome for MIS patients with or without SVE.

Acknowledgments

This work is supported by a grant from the Medical Research Council, affiliated Shu Yang People's Hospital, XuZhou Medical University, China.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of manuscript.

Author Contributions

Conceived and designed the experiments: GSW DMT.

Performed the experiments: GSW DMT.

Analyzed the data: DMT.

Contributed reagents/materials/analysis tools: GSW DMT XDC THY YTZ XBM.

Wrote the paper: DMT.

Agree with manuscript results and conclusions: GSW DMT XDC THY YTZ XBM.

References

1. Wang L, Chao Y, Zhao X, Liu L, Wang C, Wang DZ, et al. (2013) Factors associated with delayed presentation in patients with TIA and minor stroke in China: analysis of data from the China National Stroke Registry (CNSR). Neurol Res. 35:517–521. doi: 10.1179/1743132813Y.0000000204 PMID: 23711326

2. Chandrathave A, Lasserson DS, Geraghty OC, Rothwell PM. (2010) Population-based study of behavior immediately after transient ischemic attack and minor stroke in 1000 consecutive patients: lessons for public education. Stroke. 41:1108–1114. doi: 10.1161/STROKEAHA.109.576611 PMID: 20395614

3. Mahmood SS, Levy D, Vasan RS, Wang TJ (2014) The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 383: 999–1008 doi: 10.1016/S0140-6736(13)61752-3 PMID: 24084292

4. Bos MJ, Koudstaal PJ, Hofman A, Ikram MA. (2014) Modifiable etiological factors and the burden of stroke from the Rotterdam study: a population-based cohort study. PLoS Med. 11:e1001634. doi: 10.1371/journal.pmed.1001634. eCollection 2014. PMID: 24781247

5. Peters SA, Huxley RR, Woodward M. (2014) Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,885 individuals and 12,539 strokes. Lancet. 383:1973–80. doi: 10.1016/S0140-6736(14)60040-4 PMID: 24613026

6. Mallmann AB, Fuchs SC, Gus M, Fuchs FD, Moreira LB. (2012) Population-attributable risks for ischemic stroke in a community in South Brazil: a case-control study. PLoS ONE 7: e35680. doi: 10.1371/journal.pone.0035680 PMID: 22530066

7. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 378:31–40. doi: 10.1016/S0140-6736(11)60679-X PMID: 21705089

8. Abboud H, Labreuche J, Arauz A, Bryer A, et al. (2013) Demographics, socio-economic characteristics, and risk factor prevalence in patients with non-cardioembolic ischaemic stroke in low- and middle-income countries: the OPTIC registry. Int J Stroke. 10:4–13.
9. Osborn MF, Miller CC, Badr A, Zhang J. (2014) Metabolic syndrome associated with ischemic stroke among the Mexican Hispanic population in the El Paso/US-Mexico border region. J Stroke Cerebrovasc Dis. 23:1477–84. doi:10.1016/j.jstrokecerebrovasdis.2013.12.017 PMID: 24548371

10. Alberti KG, Zimmet P, Shaw J. (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diab Med 23:469–84. doi:10.1016/j.diabet.2005.08.008 PMID: 16043803

11. Bang OY, Kim JW, Lee JH, Lee MA, Lee PH, et al. (2005) Association of the metabolic syndrome with intracranial atherosclerotic stroke. Neurology. 65:296–298. PMID: 16157765

12. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. (2005) Diagnosis and Management of the Metabolic Syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 112:2735–52. PMID: 24548371

13. Li W, Liu M, Song YZ, et al. (2009) Association between metabolic syndrome and prognosis in acute ischemic non-embolic stroke. Zhonghua Yi Xue Za Zhi. 27; 89:2759–63. PMID: 20137598

14. Milionis HJ, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS. (2005) Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke. 36(7):1372–6. PMID: 15933255

15. Mi D, Zhang L, Wang C, Liu L, Pu Y, et al. (2012) Impact of metabolic syndrome on the prognosis of ischemic stroke secondary to symptomatic intracranial atherosclerosis in Chinese patients. PLoS One. 7:e51421. doi:10.1371/journal.pone.0051421 PMID: 23251528

16. Tuttolomondo A, Di Raimondo D, Di Sciacca R, Pecoraro R, Armao V, Buttà C, et al. (2012) Arterial stiffness and ischemic stroke in subjects with and without metabolic syndrome. Atherosclerosis. 225 (1):216–9. doi:10.1016/j.atherosclerosis.2012.08.027 PMID: 23031362

17. Tuttolomondo A, Pecoraro R, Di Raimondo D, Di Sciacca R, Canino B, Armao V, et al. (2014) Immune-inflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke with and without metabolic syndrome. Diabetol Metab Syndr.; 6(1):28. doi:10.1186/1758-5996-6-28 PMID: 24571954

18. Fischer U, Baumgartner A, Arnold M, Nedeltchev K, Gralla J, De Marchis GM, et al. (2010) What is a minor stroke? Stroke. 41:661–666 doi:10.1161/STROKEAHA.109.572883 PMID: 20185781

19. Wang X, Lam WW, Fan YH, Graham CA, Rainer TH, Wong KS. (2006) Topographic patterns of small subcortical infarcts associated with MCA stenosis: a diffusion-weighted MRI study. J Neuroimaging. 16:266–71 PMID: 16808829

20. Potter GM, Marlborough FJ, Wardlaw JM. (2011) Wide variation in definition, detection, and description of lacunar lesions on imaging. Stroke. 42:359–366. doi:10.1161/STROKEAHA.110.594754 PMID: 21193752

21. Kono Y, Yamada S, Kamisaka K, Araki A, Fujioka Y, Yasui K, et al. (2011) Recurrence risk after noncardioembolic mild ischemic stroke in a Japanese population. Cerebrovasc Dis. 31:365–72. doi:10.1159/000323233. Epub 2011 Jan 19. PMID: 21252505

22. Koren-Morag N, Goldbourt U, Tanne D. (2005) Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke. 36:1366–71. PMID: 15933253

23. Chen YC, Sun CA, Yang T, et al. (2014) Impact of metabolic syndrome components on incident stroke subtypes: a Chinese cohort study. J Hum Hypertens. 28:689–93. doi: 10.1038/jhh.2013.152 PMID: 24430706

24. Fang X, Liu H, Zhang X, Zhang H, Qin X, Ji X. (2016) Metabolic syndrome, Its Components, and Diabetes on 5-Year Risk of Recurrent Stroke among Mild-to-Moderate Ischemic Stroke Survivors: A Multicentric Registry Study. J Stroke Cerebrovasc Dis. 2016 Mar; 25:626–34. doi: 10.1016/j.jstrokecerebrovasdis.2015.11.017

25. Liu L, Zhan L, Wang Y, et al. (2015) Metabolic syndrome and the short-term prognosis of acute ischemic stroke: a hospital-based retrospective study. Lipids Health Dis. 22:14:76. doi:10.1186/s12944-015-0080-8 PMID: 26199022

26. Lucke-Wold BP, Turner RC, Lucke-Wold AN, Rosen CL, Huber JD. (2012) Age and the metabolic syndrome as risk factors for ischemic stroke: improving preclinical models of ischemic stroke. Yale J Biol Med. 85:523–39. PMID: 23239952

27. Toni D, Di Angelantonio E, Di Mascio MT, Vinisko R, Bath PM. (2013) Types of stroke recurrence in patients with ischemic stroke: A study from the PRoFESS trial. Int J Stroke. 22. doi: 10.1111/ijis.12150

28. Lim S, Shin H, Song JH, Kwak SH, Kang SM, Won Yoon J, et al. (2011) Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998–2007. Diabetes Care. 34:1323–1328. doi:10.2337/dc10-2109 PMID: 21505206
29. Suh Sunghwan, Baek Jongha, Bae Ji Cheol, et al. (2014) Sex Factors in the Metabolic Syndrome as a Predictor of Cardiovascular Disease. Endocrinol Metab. 29: 522–529.

30. Purroy F, Montaner J, Rovira A, Delgado P, Quintana M, Alvarez-Sabin J (2004) Higher risk of further vascular events among transient ischemic attack patients with diffusion-weighted imaging acute ischemic lesions. Stroke; 35: 2313–2319. PMID: 15322305

31. Brisset M, Boutouyrie P, Pico F, Zhu Y, Zureik M, Schilling S, et al. (2013) Large-vessel correlates of cerebral small-vessel disease. Neurology; 80:662–669 doi: 10.1212/WNL.0b013e318281ccc2 PMID: 23345633

32. Wang A, Li Z, Luo Y, Liu X, Guo X, Wu S, et al. (2014) Asymptomatic Intracranial Arterial Stenosis and Metabolic Syndrome: The APAC Study. PLoS ONE 9(12): e113205. doi: 10.1371/journal.pone.0113205 PMID: 25463628